Received Mar 23, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| TYP | TYPHOID LIVE ORAL TY21A (VIVOTIF) | BERNA BIOTECH, LTD. | 2 | Unknown | PO / MO |
The patient took the first and the second dose of Vivotif correctly and then took a five to six days vacation and has not finished the other two doses; Case reference number US-BN-2024-002194 is a spontaneous case initially received from other health care professional via agency (reference number USBAV24-1665) on 15-Jul-2024 and concerns a female patient of unspecified age. The patient's medical history and concomitant medication details were not provided. On unspecified dates, reported as correctly, the patient took the first and the second dose of Vivotif (batch number: unknown), the dose was unknown, orally for unknown indication. As reported, then patient took a five to six days of vacation and has not finished the other two doses (explicitly coded as 'inappropriate schedule of vaccine administered'). At the time of the initial report, it was unknown if the patient experienced any adverse event due to Vivotif. Non-significant follow up was downloaded from VAERS on 09-May-2025 included new reference number Administrative update performed within the case: Worldwide Unique Case Identification Number (WWID) updated from US-20240715-99d9a6 to US-BAVARIAN NORDIC A/S-US-BN-2024-002194, in accordance with ICH guidance on WWID formatting.; Reporter's Comments: A female patient of unspecified age took the first and the second dose of Vivotif for unknown indication. As reported, then patient took a five to six days of vacation and has not finished the other two doses, which is considered as inappropriate schedule of vaccine administered. It was unknown if the patient experienced any adverse event due to Vivotif. Inappropriate schedule of product administration is considered as listed per company convention. The patient's medical history and concomitant medication details were not provided. Inappropriate schedule of product administration is not related to the suspect vaccine, but to a human factor. This case is considered as non-serious.; Sender's Comments: A female patient of unspecified age took the first and the second dose of Vivotif for unknown indication. As reported, then patient took a five to six days of vacation and has not finished the other two doses, which is considered as inappropriate schedule of vaccine administered. It was unknown if the patient experienced any adverse event due to Vivotif. Inappropriate schedule of product administration is considered as listed per company convention. The patient's medical history and concomitant medication details were not provided. Inappropriate schedule of product administration is not related to the suspect vaccine, but to a human factor. This case is considered as non-serious.
Comments: None